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mg, resulting in ~25% greater 24-hour urinary glucose excretion. In addition, CANA 
300 mg may transiently block intestinal SGLT1, delaying glucose absorption and 
reducing postprandial glucose. METHODS: The IMS CORE Diabetes Model was used 
to evaluate the cost-effectiveness of CANA 100 and 300 mg versus DAPA 10 mg using 
Spanish-specific utilities and cost data. Direct costs were reported in euros and an 
annual discount rate of 3% was applied to costs and effects. The time horizon used 
for the economic evaluation was 40 years to reflect the chronic nature of the disease. 
A randomised, controlled trial of CANA in dual therapy and an NMA were sourced for 
initial patient characteristics and treatment effects. Results were compared with the 
willingness-to-pay (WTP) threshold reported for Spain (€ 30,000/QALY). RESULTS: 
CANA 100 mg dominated DAPA in dual therapy, with 0.061 quality-adjusted life years 
(QALYs) gained. CANA 300 mg was cost-effective compared to DAPA 10 mg in dual 
therapy with a cost-effectiveness ratio below the WTP threshold in Spain; QALYs 
gained were 0.084. CONCLUSIONS: These results suggest that adding CANA 100 or 
300 mg instead of DAPA 10 mg in patients inadequately controlled on metformin 
would result in more efficient use of healthcare resources in the Spanish setting.
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OBJECTIVES: Proper glycemic control reduces the frequency of microvascular and 
macrovascular complications in type 2 diabetes. Many patients require more than 
one medication to reach goal glycated hemoglobin (A1c) levels. The objective of 
this study was to assess the cost-effectiveness of dapagliflozin versus the dipepti-
dyl pepdtidase 4-inhibitors in regards to cost per unit of A1c lowered. METHODS: 
Data for clinical outcomes were abstracted from a meta-analysis comparing the 
effectiveness of oral diabetes medications added to metformin for type 2 diabetic 
patients failing to achieve goal Alc levels with metformin alone. All comparisons in 
the meta-analysis were for a 52 week period. A random effects regression model was 
utilized to compare dapagliflozin to dipeptidyl peptidase 4-inhibitors in their ability 
to lower glycemic levels after adjusting for baseline Alc and additional covariates. 
The costs for the antidiabetic agents were based on published wholesale acquisition 
costs data for 2014. An incremental cost effectiveness ratio (ICER) was calculated 
to determine cost per additional percentage point for lowering the A1c from the 
health payer perspective. RESULTS: Dapagliflozin was more effective than dipepti-
dyl pepdtidase 4-inhibitors in lowering A1c levels and was associated and additional 
0.07% lowering of the A1c level after adjusting for covariates. Dapagliflozin was more 
expensive at an annual cost of $3,470.40 while dipeptidyl pepdtidase 4-inhibitors 
had an annual costs of $3,405.60. The resulting ICER indicated that there was a cost 
$926 for each additional percentage point that the Alc was lowered by using dapagli-
flozin. CONCLUSIONS: Dapagliflozin was more effective than dipeptidyl pepdtidase 
4-inhibitors in lowering A1c levels, yet it was also more expensive. Decision makers 
trying to decide whether or not to use these medications must be prepared to decide 
if the additional benefit is worth the cost.
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OBJECTIVES: To evaluate the CE ratio of empagliflozin 25mg compared to sitagliptin 
100mg when added to MET in patients with T2DM. METHODS: A discrete event simu-
lation CE model was developed to assess the life years (LY) gained and the treatment 
related costs associated with the studied alternatives in a 10-year horizon. Relevant 
clinical outcomes identified where efficacy (HbA1c, systolic blood pressure and weight 
reductions), safety (severe and non-severe hypoglycemia episodes, urinary and geni-
tal infections) and treatment-related complications including discontinuation. The 
results of a Network-Meta-Analysis where taken as efficacy and safety inputs of the 
model. Public institutional direct medical costs (2014 purchases and price tabulators) 
where retrieved to adopt the national health system perspective. A probabilistic sen-
sitivity analysis was performed to endorse the results. RESULTS: In the 10-year time 
horizon adopted, and after running 5000 simulations per treatment arm, sitaglitpin 
100mg was estimated to have the highest cost of treatment with $179,124.75 MX 
against $175,842.69 MX reported by empagliflozin 25mg. A small positive difference 
of 0.009 in LY gained was to be seen in the empagliflozin 25mg arm with an estimate 
of 4.166 when compared to the sitagliptin 100mg arm with 4.157. Results in the incre-
mental CE ratio (ICER) favored empagliflozin 25mg as a dominant therapy against 
sitagliptin 100mg. Results were sensitive to changes in efficacy inputs and costs; 
probabilistic results were scattered, with a discrete trend towards the cost-saving 
and cost-effective planes. CONCLUSIONS: With a lower cost of treatment at a better 
LY saved level, empagliflozin was estimated to be a cost-saving alternative versus 
sitagliptin when added to MET for patients with T2DM.
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OBJECTIVES: Assess cost-effectiveness of second- and third-line therapies, respec-
tively, in type 2 diabetes, from the Taiwan’s National Health Insurance (NHI) per-
spective. METHODS: Patients, treatment and costs data were gathered from the 
NHI Research Database linked with the National Mortality Registry. There were 
five metformin-dual therapy cohorts: a reference - metformin plus sulphonylureas 
(Met-SU); four comparisons - metformin plus acarbose (Met-ACA), metformin plus 
9.06 QALY. The reason of utility cost was U$1,006.03 and U$2,331.98 respectively. 
According to sensitivity analysis for drug prices (minimum and maximum), NPH 
was considered alternative more cost-effective in all scenarios. Exchange R$2, 67 = 
U$ 1.00 (Jan/15) CONCLUSIONS: Considering the similarity of the results obtained 
from the analysis of effectiveness and utility in comparing Glargine versus NPH 
at MD treatment, it is concluded that the difference remains only in the costs of 
treatment: Glargine costs are higher.
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OBJECTIVES: In Canada, the most commonly utilized oral third-line agent for 
patients with T2DM inadequately controlled on metformin (MET) and a sulfony-
lurea (SU) is sitagliptin (SITA). Canagliflozin (CANA), a novel agent that inhibits 
sodium glucose co-transporter 2 (SGLT2), has demonstrated HbA1c lowering, as 
well as improvements in weight and systolic blood pressure (SBP). The objec-
tive of this analysis was to evaluate the cost-effectiveness of CANA 100 and 300 
mg versus SITA 100 mg in patients inadequately controlled on MET + SU in the 
Canadian setting. METHODS: In accordance with the CADTH guidelines for eco-
nomic evaluations, cost-utility analysis using ECHO-T2DM, a validated economic 
model, was done to simulate lifetime outcomes and costs of using CANA versus 
SITA in the third-line setting. Patient characteristics and treatment effects were 
sourced from a head-to-head study for the comparison of CANA 300 mg to SITA 
100 mg. In the absence of a direct comparison of CANA 100 mg versus SITA 100 
mg, relative treatment effects for this simulation were obtained from an indirect 
comparison via Bayesian network meta-analysis (NMA), with baseline patient 
characteristics sourced from a pooled analysis of two CANA trials (patients on 
background therapy of MET + SU) that contributed to the NMA. ECHO-T2DM was 
populated with Canadian costs and utility estimates relevant to the Canadian pop-
ulation. RESULTS: Using CANA 300 and 100 mg resulted in mean quality-adjusted 
life year (QALY) gains of 0.08 and 0.04, respectively, and lower costs of $2,035 and 
$981, respectively, compared to SITA over 40 years in patients failing to meet gly-
cemic control on MET + SU. Therefore, CANA “dominated” SITA. CONCLUSIONS: 
CANA used as a third-line agent added on to MET + SU background therapy may 
result in better quality of life outcomes and lower costs when compared to SITA 
(the most common third-line agent in Canada).
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OBJECTIVES: The association between rare genetic disorders, hereditary fructose 
intolerance (HFI) or alpha-1 antitrypsin deficiency (A1AT), and type 2 diabetes 
(T2D) has not yet been investigated. Therefore, the objective of this undertaking 
was to evaluate the association between both genetic disorders and T2D using 
four large observational databases and adjust for ascertainment bias. METHODS: 
Patients with a HFI diagnosis (ICD-9: 271.2) or A1AT diagnosis (ICD-9: 273.4) and 
T2D diagnosis (ICD-9: 250.x0 or 250.x2) were identified in the Truven MarketScan 
Claims Database (2007-2012), Optum Claims Database (2002-2012), Humedica 
Electronic Health Records (EHR) Database (2007-2012), and GE Centricity EHR 
Database (1995-2012). The association between both genetic disorders and T2D 
was compared to the association between T2D and seven negative control chronic 
diseases with no established relationship with T2D. RESULTS: The unadjusted 
association between both genetic disorders and T2D was positive and hetero-
geneous (p<0.001) in all four databases. The unadjusted pooled odds ratio (OR) 
calculated using a random-effects model meta-analysis was 3.48 (95% CI: 2.21-
5.46) for HFI and 2.71 for A1AT (95% CI: 1.75-4.20). After pooling all patients and 
adjusting for the negative controls using a random-effects model meta-analysis, 
it was found that HFI patients have a 73% increased odds of T2D (ratio of odds 
ratios [ROR]=1.73, 95% CI: 1.08-2.75) compared to patients with negative control 
diseases; the association was stronger when utilizing a fixed-effects model meta-
analysis (ROR=2.19, 95% CI: 2.07-2.31). The adjusted association between A1AT and 
T2D was statistically significant in the fixed-effects (ROR=1.33, 95% CI: 1.27-1.40) 
model meta-analysis but not the random-effects model meta-analysis (ROR=1.35, 
95% CI: 0.86-2.12). CONCLUSIONS: HFI and T2D were positively associated after 
adjustment for negative control chronic diseases in both meta-analysis models. 
Rare disease researchers using observational data to conduct comorbidity analyses 
can utilize negative controls and multiple datasets to account for ascertainment 
bias and database heterogeneity, respectively.
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OBJECTIVES: To compare the cost-effectiveness of canagliflozin (CANA) and dapagli-
flozin (DAPA), two compounds with sodium glucose co-transporter 2 (SGLT2) activity, 
in dual therapy as add-on to metformin from the Spanish National Health System 
perspective. Network meta-analyses (NMAs) have found that CANA 300 mg lowers 
HbA1c more than DAPA 10 mg in dual and triple therapy. Pharmacokinetic and 
pharmacodynamic differences support these results. Specifically, CANA 300 mg has 
been shown to reduce the renal threshold for glucose excretion more than DAPA 10 
